header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

Management of hip fracture patients on warfarin for atrial fibrillation

British Orthopaedic Association/Irish Orthopaedic Association Annual Congress (BOA/IOA)



Abstract

Introduction

It is estimated 5% of patients over 65 years receive warfarin therapy. This paper aims to analyse whether a time delay to hip fracture fixation while waiting for the patients International Normalised Ratio (INR) to return to normal increases the mortality risk.

Methods

A prospective database of 937 hip fractures was analysed. Patient demographics and time from admission to operation were recorded. The patients' INR on admission and during the preoperative period, the need for vitamin K reversal, and any postoperative thromboembolic compilations were recorded. Thirty-day mortality was obtained from the General Register Office for Scotland. Patients with a therapeutic INR were categorised into two groups: those who received vitamin K within 24 hours of admission and those who did not.

Results

There were 27 patients (74% female, mean age 80.9 years) receiving warfarin for atrial fibrillation. Two patients had a subtherapeutic INR on admission and were excluded from further analysis. Nine of eleven patients receiving vitamin K (mean dose 1.3mg) had surgery within 48 hours of admission, whereas only five of the fourteen patients who did not receive vitamin K had surgery within this time (OR3.6, p=0.047). There were no thromboembolic complications during admission for either group. Thirty-day mortality was increased for both groups relative to standard rate (OR1.5, p=0.5, and OR2.4 p=0.2 respectively), but there was no significant difference between the groups (p=0.9).

Conclusion

Patients with a fractured hip who are receiving warfarin for atrial fibrillation and have a therapeutic INR should receive low dose vitamin K on admission to facilitate early operative intervention and rehabilitation.